is a Frequent Biomarker of Adverse Prognosis in Mexican Pediatric Patients with B-acute Lymphoblastic Leukemia

Background: Recurrent genetic alterations contributing to leukemogenesis have been identified in pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL), and some are useful for refining classification, prognosis, and treatment selection. is a complex biomarker associated with a poor prognosis. It is characterized by deletion coexisting with , , or PAR1 region deletions. The mutational spectrum and clinical impact of these alterations have scarcely been explored in Mexican pediatric patients with B-ALL. Here, we report the frequency of the profile and the mutational spectrum of , and genes and evaluate their impact on overall survival (OS) in a group of patients with B-ALL.

Methods: A total of 206 pediatric patients with B-ALL were included. DNA was obtained from bone marrow samples at diagnosis before treatment initiation. A custom-designed next-generation sequencing panel was used for mutational analysis. Kaplan-Meier analysis was used for OS estimation.

Results: We identified the profile in 21.8% of patients, which was higher than that previously reported in other studies. A significantly older age (), a trend toward high-risk stratification (), and a decrease in 5-year Overall Survival (OS) () were observed, although heterogeneous treatment protocols in our cohort would have impacted OS. A mutation frequency higher than that reported was found for (35.9%) and (35.9%) but lower for (26.6%). group was older at diagnosis (), and most of them were classified as high-risk (73.8%, ), while patients with had a higher leukocyte count () and a tendency toward a higher percentage of blasts (98.6%, >50% blasts, ) than the non-mutated patients. A decrease in OS was found in and patients, but the significance was lost after was removed.

Discussion: Our findings demonstrated that Mexican patients with B-ALL have a higher prevalence of genetic markers associated with poor outcomes. Incorporating genomic methodologies into the diagnostic process, a significant unmet need in low- and mid-income countries, will allow a comprehensive identification of relevant alterations, improving disease classification, treatment selection, and the general outcome.

Citing Articles

Editorial: Childhood leukemias in Latin America: epidemiology, causality, novel predictive profiles and therapeutic strategies.

Nunez-Enriquez J, Mejia-Arangure J, Cruz-Munoz M, Pelayo R Front Oncol. 2024; 14:1509943.

PMID: 39624629 PMC: 11609072. DOI: 10.3389/fonc.2024.1509943.

References

Rosales-Rodriguez B, Nunez-Enriquez J, Velazquez-Wong A, Gonzalez-Torres C, Gaytan-Cervantes J, Jimenez-Hernandez E . Copy Number Alterations are Associated with the Risk of Very Early Relapse in Pediatric B-lineage Acute Lymphoblastic Leukemia: A Nested Case-control MIGICCL Study. Arch Med Res. 2021; 52(4):414-422. DOI: 10.1016/j.arcmed.2020.12.013. View

Waanders E, van der Velden V, van der Schoot C, van Leeuwen F, van Reijmersdal S, de Haas V . Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia. 2010; 25(2):254-8. DOI: 10.1038/leu.2010.275. View

Li J, Dai Y, Lilljebjorn H, Shen S, Cui B, Bai L . Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A. 2018; 115(50):E11711-E11720. PMC: 6294900. DOI: 10.1073/pnas.1814397115. View

Gupta S, Singh M, Chandrashekar P, Bakhshi S, Trehan A, Gupta R . Clinical and Prognostic Impact of Copy Number Alterations and Associated Risk Profiles in a Cohort of Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Cases Treated Under ICiCLe Protocol. Hemasphere. 2022; 6(10):e782. PMC: 9529051. DOI: 10.1097/HS9.0000000000000782. View

Castro-Rios A, Reyes-Morales H, Pelcastre-Villafuerte B, Rendon-Macias M, Fajardo-Gutierrez A . Socioeconomic inequalities in survival of children with acute lymphoblastic leukemia insured by social security in Mexico: a study of the 2007-2009 cohorts. Int J Equity Health. 2019; 18(1):40. PMC: 6399870. DOI: 10.1186/s12939-019-0940-3. View

Mullighan C, Su X, Zhang J, Radtke I, Phillips L, Miller C . Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5):470-80. PMC: 2674612. DOI: 10.1056/NEJMoa0808253. View

Zhang W, Kuang P, Liu T . Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Ann Med. 2018; 51(1):28-40. PMC: 7857473. DOI: 10.1080/07853890.2018.1564359. View

Jean J, Kovach A, Doan A, Oberley M, Ji J, Schmidt R . Characterization of PAX5 intragenic tandem multiplication in pediatric B-lymphoblastic leukemia by optical genome mapping. Blood Adv. 2022; 6(11):3343-3346. PMC: 9198916. DOI: 10.1182/bloodadvances.2021006328. View

Rebollo A, Schmitt C . Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol Cell Biol. 2003; 81(3):171-5. DOI: 10.1046/j.1440-1711.2003.01159.x. View

10.

Ayon-Perez M, Pimentel-Gutierrez H, Duran-Avelar M, Vibanco-Perez N, Perez-Peraza V, Perez-Gonzalez O . IKZF1 Gene Deletion in Pediatric Patients Diagnosed with Acute Lymphoblastic Leukemia in Mexico. Cytogenet Genome Res. 2019; 158(1):10-16. DOI: 10.1159/000499641. View

11.

Perez-Saldivar M, Fajardo-Gutierrez A, Bernaldez-Rios R, Martinez-Avalos A, Medina-Sanson A, Espinosa-Hernandez L . Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer. 2011; 11:355. PMC: 3171387. DOI: 10.1186/1471-2407-11-355. View

12.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

13.

Graf Einsiedel H, Taube T, Hartmann R, Wellmann S, Seifert G, Henze G . Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia. Blood. 2002; 99(12):4629-31. DOI: 10.1182/blood.v99.12.4629. View

14.

Schwab C, Cranston R, Ryan S, Butler E, Winterman E, Hawking Z . Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia. 2022; 37(3):529-538. PMC: 9991913. DOI: 10.1038/s41375-022-01799-4. View

15.

Rivera-Luna R, Zapata-Tarres M, Shalkow-Klincovstein J, Velasco-Hidalgo L, Olaya-Vargas A, Finkelstein-Mizrahi N . The burden of childhood cancer in Mexico: Implications for low- and middle-income countries. Pediatr Blood Cancer. 2016; 64(6). DOI: 10.1002/pbc.26366. View

16.

Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer J . Intragenic amplification of : a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Adv. 2018; 1(19):1473-1477. PMC: 5728462. DOI: 10.1182/bloodadvances.2017006734. View

17.

Agarwal M, Bakhshi S, Dwivedi S, Kabra M, Shukla R, Seth R . Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018; 65(6):e27001. DOI: 10.1002/pbc.27001. View

18.

Lee S, Yang W, Gocho Y, John A, Rowland L, Smart B . Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. Nat Med. 2023; 29(1):170-179. PMC: 9873558. DOI: 10.1038/s41591-022-02112-7. View

19.

Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I . P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2018; 133(3):280-284. DOI: 10.1182/blood-2018-10-882142. View

20.

Morel G, Deau M, Simand C, Caye-Eude A, Arfeuille C, Ittel A . Large deletions of the 5' region of IKZF1 lead to haploinsufficiency in B-cell precursor acute lymphoblastic leukaemia. Br J Haematol. 2019; 186(5):e155-e159. DOI: 10.1111/bjh.15994. View